Novavax | NVAX - Current Assets


Novavax reported $850.82M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Adma Biologics USD 511.17M 44.66M Mar/2026
Agenus USD 95.28M 38.15M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Cassava Sciences USD 87.96M 9.74M Mar/2026
Geron USD 498.53M 21.74M Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
MannKind USD 251.16M 40.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 5.77B 774M Mar/2026
Novartis USD 30.46B 2.26B Dec/2025
Novavax USD 850.82M 127.46M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
TG Therapeutics USD 1.09B 456.2M Mar/2026